Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
49.12
-1.61 (-3.17%)
Apr 27, 2026, 11:06 AM EDT - Market open
← View all transcripts

AGM 2024

May 6, 2024

Noubar Afeyan
Chairman of the Board, Moderna

Good morning. I'm Noubar Afeyan, Chairman of the Board of Moderna. Thank you for joining us this morning, and welcome to the Moderna 2024 annual meeting, shareholders. Before I call the meeting to order, I'd like to introduce to you the members of the board and the executives who are joining us today. I'm accompanied today by Stéphane Bancel, our CEO, and a fellow director. The rest of our board is joining us virtually today: Stephen Berenson, Sandra Horning, Paul Sagan, Liz Nabel, François Nader, Paul Sagan, and Elizabeth Tallett. Moderna is indeed fortunate to have such a capable and committed board who partner with management in making sure Moderna's Moderna can have as positive an impact on human health as possible.

Now, the members of Moderna's executive committee joining us in person and virtually today are Jerh Collins, Kate Cronin, Tracey Franklin, Stephen Hoge, Shannon Klinger, Brad Miller, and Jamey Mock. Ms. Klinger, Moderna's Chief Legal Officer and Corporate Secretary, will serve as the secretary for this meeting. We're also joined today by Chris Pereira, the lead partner for Ernst & Young, Moderna's independent registered public accounting firm, who is available to respond to appropriate questions. The meeting will now officially come to order. We will proceed with the formal business of the meeting as set forth in your notice of annual meeting and proxy statement, which was sent to all shareholders of record as of the close of business on March 7, 2024. Following the presentation of the proposals and before the polling is closed, there will be an opportunity for shareholders to submit questions specific to those items.

After the formal part of our meeting, we will also address relevant questions that are submitted by shareholders through the virtual meeting platform. The meeting will be conducted in accordance with the rules of conduct that you have access to on the meeting website. Will the secretary please report, at this time, respecting the mailing of the notice of the meeting and the shareholders list?

Shannon Klinger
Chief Legal Officer, Moderna

Thank you, Mr. Chairman. A complete list of the shareholders of record of the company's common stock on March 7th, 2024, the record date for this meeting, has been on file with my office for the last 10 days prior to the date of this meeting and has been available for inspection by any shareholder during that period at any time during normal business hours in accordance with Delaware law. I also have an affidavit certifying that commencing March 21st, 2024, the company's annual report on Form 10-K, annual meeting notice, proxy statement, and proxy card were deposited in the United States mail to each of the shareholders of record at the close of business on March 7th, 2024, designated to receive a full set delivery.

Noubar Afeyan
Chairman of the Board, Moderna

At this time, I'd like to introduce Jennifer Burden. Ms. Burden has been appointed by the board to act as inspector of election at this meeting. She has taken and subscribed to the customary oath of office to execute her duties with strict impartiality. She will file this oath for the records of the meeting. Her function is to decide upon the qualifications of voters, accept their votes, and, when balloting on all matters is completed, to tally the final votes. Will the secretary please report at this time with respect to the existence of a quorum?

Shannon Klinger
Chief Legal Officer, Moderna

I have been informed by the inspector of election that proxies have been received for at least a majority of the shares of common stock outstanding on the record date. This constitutes a quorum for the meeting today, and we may now carry out the official business of the meeting.

Noubar Afeyan
Chairman of the Board, Moderna

Will the secretary please review the voting procedures?

Shannon Klinger
Chief Legal Officer, Moderna

Voting today is by proxy and virtual ballot. It is not necessary for shareholders to vote by virtual ballot if they have already submitted their proxy cards unless they wish to change their vote. Virtual ballots are available for any shareholder who wishes to vote by virtual ballot or to change their vote. Shareholders who are logged in using their control number may change their vote by clicking on the vote link on the website. Your submission of a virtual ballot will revoke all prior proxies. Each share of common stock is entitled to one vote.

Noubar Afeyan
Chairman of the Board, Moderna

We will now proceed with the formal business of this meeting and the agenda that is accessible to you on the meeting site. There are five matters to be considered by the shareholders at this meeting: the election of directors, approval of a non-binding advisory vote to approve the compensation of our executive officers, the ratification of the independent registered public accounting firm, Ernst & Young LLP, for the year ended December 31, 2024, a management proposal to amend our certificate of incorporation to provide shareholders the right to call a special meeting, and a management proposal to amend our certificate of incorporation to reflect new Delaware law provisions allowing for officer exculpation. The secretary will now declare the polls open.

Shannon Klinger
Chief Legal Officer, Moderna

The virtual voting tab is now open for voting on all matters to be presented. The virtual voting tab will be closed to voting after we go through the matters to be voted upon. Questions that are specific to these items may be submitted on the platform.

Noubar Afeyan
Chairman of the Board, Moderna

The first item of business is the election of the Class III directors to serve until the 2027 annual meeting and until their successors are duly elected and qualified, or such directors' earlier death, resignation, or removal. Based on the recommendation of the Nominating and Corporate Governance Committee of the board, the nominees for Class III Director are Robert Langer, Elizabeth Nabel, and Elizabeth Tallett. All three nominees are current members of our board, and all three have consented to serve if elected. For Proposal 1, the election of our Class III directors requires a majority vote for the shares of our common stock voting at this meeting. No other persons having been nominated in accordance with the company's amended and restated bylaws. The nominations are now closed. The Board of Directors unanimously recommends that shareholders vote in favor of this proposal.

The second item of business today is the approval on a non-binding advisory basis of the compensation of our named executive officers. As required by Section 14 A1 of the Exchange Act, the board is providing shareholders with an opportunity to approve on a non-binding advisory basis the compensation of our named executive officers as described in detail in the proxy. The board unanimously recommends that shareholders vote for approval and on a non-binding advisory basis of the compensation of the company's named executive officers. The third item of business today is the ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the company for the fiscal year ending December 31, 2024.

For Proposal three, a majority of the votes properly cast is required in order to ratify the appointment of Ernst & Young LLP. In the event that a majority of the votes properly cast do not ratify the appointment of Ernst & Young LLP, we will review our future appointment of Ernst & Young LLP. The fourth item of business today is a vote on the management proposal requesting approval of an amendment to our certificate of incorporation to provide shareholders the right to call a special meeting. The Board of Directors unanimously recommends that shareholders vote in favor of this proposal for the reasons set forth in the proxy. The final item of business today is a vote on the management proposal requesting approval of an amendment to our certificate of incorporation to reflect new Delaware law provisions allowing for officer exculpation.

The Board of Directors unanimously recommends that shareholders vote in favor of this proposal for the reasons set forth in the proxy. We will now proceed with the voting. Anyone who is voting by virtual ballot and has not already done so during the meeting, please click on the voting button on the virtual platform and mark your virtual ballot now. We will give everyone a moment to mark their virtual ballots. The inspector of elections will not accept virtual ballots, proxies, or votes, or any changes or revocations submitted after the closing of the polls. The time is 8:08 A.M. on May 6, 2024, and the polls for each matter to be voted on at this meeting are now closed for voting. No additional virtual ballots, proxies, or votes, and no changes or revocations will be accepted. May we have the preliminary results of the voting?

Shannon Klinger
Chief Legal Officer, Moderna

The preliminary report of the inspector of election covering the proposals presented at this meeting is as follows. Regarding the first proposal, each of Robert Langer, Elizabeth Nabel, and Elizabeth Tallett has received the requisite number of votes in favor of their election, and each has been elected as a Class III Director. The second proposal, to approve on a non-binding advisory basis the compensation of our named executive officers, has received the requisite number of votes in favor, and the compensation of the named executive officers is approved. The third proposal, to ratify the selection of Ernst & Young LLP as the company's independent registered public accounting firm for the year ending December 31st, 2024, has received the requisite number of the votes in favor of their ratification. Their appointment is ratified.

The fourth proposal, a management proposal requesting approval to amend our certificate of incorporation to provide shareholders the right to call a special meeting, has received the requisite number of votes in favor and is approved. The fifth proposal, a management proposal requesting approval to amend our certificate of incorporation to reflect new Delaware law provisions allowing for officer exculpation, has received the requisite number of votes in favor and is approved. The final results of voting, including any virtual ballots and proxies recorded during this meeting, will be set forth in the report of the inspector of elections and will be included in the minutes of the meeting. We will report our final voting results on a current report on Form 8-K to be filed with the SEC within four business days.

Noubar Afeyan
Chairman of the Board, Moderna

I declare that all of the management proposals presented at the meeting have been ratified or approved by the shareholders, and there being no further business, the annual meeting is adjourned. Let me now ask Stéphane Bancel, our Chief Executive Officer, and Shannon Klinger, our Chief Legal Officer, to join me in addressing any questions that have been submitted during the meeting. We solicited questions in advance of the meeting from shareholders and only received a small number, all of which were either comments or specific to the investor, and have addressed those comments or questions directly.

Shannon Klinger
Chief Legal Officer, Moderna

We received several questions in the queue. We have a question from a shareholder about our pipeline and technological developments. We encourage our shareholders to look at the replay from our recent Vaccines Day presentation, which is available on the Moderna Investor Relations website. Another investor asks about the recently implemented majority voting standard for our bylaws. The provision requiring a director to tender his or her resignation for consideration by the board is one that is typical and allows the board to engage with investors to understand the reason for the vote before making a determination on whether to accept the resignation.

Noubar Afeyan
Chairman of the Board, Moderna

That will complete the question and answer. Thank you all for attending today's meeting, and thank you for your.

Powered by